COMMUNIQUÉS West-GlobeNewswire

Zymeworks to Present Clinical Data from the Phase 1 trial of ZW191, an Antibody-Drug Conjugate Targeting Folate Receptor-⍺, at AACR-NCI-EORTC International Conference
13/10/2025
Preliminary data presented at the AACR-NCI-EORTC conference will provide insights into the potential of ZW191 in patients with advanced solid tumors, including ovarian cancer, endometrial cancer, and non-small cell lung [...]
Denali Therapeutics Announces FDA Review Extension of BLA for Tividenofusp Alfa for the Treatment of MPS II (Hunter Syndrome)
13/10/2025
SOUTH SAN FRANCISCO, Calif., Oct. 13, 2025 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (Nasdaq: DNLI) today announced that the U.S. Food and Drug Administration (FDA) has extended its review timeline of the Biologics [...]
PMV Pharmaceuticals to Present Rezatapopt Pivotal Phase 2 Initial Analysis and Natural History Study Results at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
13/10/2025
Oral presentation to highlight initial data from ongoing pivotal Phase 2 study of rezatapopt, a first-in-class precision oncology investigational therapy, in patients with advanced solid tumors harboring a TP53 Y220C [...]
Spyre Therapeutics Announces Proposed Public Offering of its Common Stock and Pre-Funded Warrants
13/10/2025
WALTHAM, Mass., Oct. 13, 2025 (GLOBE NEWSWIRE) -- Spyre Therapeutics, Inc. (“Spyre” or the “Company”) (Nasdaq: SYRE), a clinical-stage biotechnology company advancing best-in-class antibody engineering, dose [...]
iMDx Welcomes New VP Marketing to Prepare for Commercial Transplant Assay Launch
13/10/2025
Steven Tahmooressi to lead global marketing efforts for GraftAssure family of assays and future products Brings 25 years of experience driving new product adoption across geographies in transplantation, oncology and [...]
BBOT Announces Poster Presentations at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
13/10/2025
SOUTH SAN FRANCISCO, Calif., Oct. 13, 2025 (GLOBE NEWSWIRE) -- BridgeBio Oncology Therapeutics, Inc. (“BBOT”) (Nasdaq: BBOT), a clinical-stage biopharmaceutical company focused on RAS-pathway malignancies, today [...]
Zentalis Pharmaceuticals Announces Four Azenosertib Posters Presentations at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
13/10/2025
Presentations feature data from first-in-human Phase 1 study including Cyclin E1 biomarker findings, supporting late-stage development of azenosertib SAN DIEGO, Oct. 13, 2025 (GLOBE NEWSWIRE) -- Zentalis® [...]
Pyxis Oncology to Present Translational Data and Key Biology Findings Elucidating the Mechanism of Action of MICVO at Upcoming Medical Meetings
13/10/2025
Translational data validate mechanism of first-in-concept extracellular-cleaving ADC micvotabart pelidotin (MICVO) MICVO combats solid tumors through three-pronged mechanism of action: direct tumor cell killing, [...]
Boundless Bio Announces Upcoming Presentation at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
13/10/2025
SAN DIEGO, Oct. 13, 2025 (GLOBE NEWSWIRE) -- Boundless Bio , (Nasdaq: BOLD) a clinical-stage oncology company interrogating extrachromosomal DNA (ecDNA) biology to deliver transformative therapies to patients with [...]
Avadel Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
13/10/2025
DUBLIN, Oct. 13, 2025 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on transforming medicines to transform lives, today announced that the Compensation Committee of Avadel’s Board of [...]
Tilray Medical Announces Expansion Plans in Panama, Strengthening Global Cannabis Leadership and Accelerating International Growth
13/10/2025
NEW YORK, Oct. 13, 2025 (GLOBE NEWSWIRE) -- Tilray Medical (“Tilray”), a division of Tilray Brands, Inc. (NASDAQ: TLRY and TSX: TLRY) and a global leader in medicinal cannabis, empowering the therapeutic alliance [...]
MAIA Biotechnology Announces $736,600 Private Placement
13/10/2025
CHICAGO, IL, Oct. 13, 2025 (GLOBE NEWSWIRE) -- MAIA Biotechnology, Inc., (NYSE American: MAIA) (“MAIA”, the “Company”), a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer, today [...]
Geron Corporation Announces Executive Leadership Transitions and Appointments
13/10/2025
Four new executives appointed, including new Chief Commercial Officer, to lead commercial strategy and operations FOSTER CITY, Calif., Oct. 13, 2025 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN), a commercial- [...]
EUROBIO SCIENTIFIC : MISE À DISPOSITION DU RAPPORT FINANCIER SEMESTRIEL 2025
13/10/2025
MISE À DISPOSITION DU RAPPORT FINANCIER SEMESTRIEL 2025 Paris, le 13 octobre 2025 – 18h30 Eurobio Scientific (FR0013240934, ALERS, éligible PEA-PME), groupe français leader dans le diagnostic médical in vitro de [...]
EUROBIO SCIENTIFIC : RAPPORT FINANCIER SEMESTRIEL AU 30 JUIN 2025
13/10/2025
EUROBIO SCIENTIFIC : RAPPORT FINANCIER SEMESTRIEL AU 30 JUIN 2025 Pièce jointe ES_Rapport_Financier_Semestriel_30062025_Final_Clean
Remix Therapeutics to Present Phase 1 Data of REM-422 at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics Conference in Late-Breaking Oral Presentation
13/10/2025
Study Evaluates Antitumor Activity and Safety of REM-422, a First/Best-in-Class Small Molecule MYB mRNA Degrader, in Patients with Adenoid Cystic Carcinoma WATERTOWN, Mass., Oct. 13, 2025 (GLOBE NEWSWIRE) -- Remix [...]
Cosmos Health Purchases an Additional $300,000 in Ethereum Under Its $300 Million Digital Assets Facility; Total Investment Reaches $1.8 Million
13/10/2025
CHICAGO, Oct. 13, 2025 (GLOBE NEWSWIRE) -- Cosmos Health Inc. ("Cosmos Health" or the “Company”) (NASDAQ:COSM) , a diversified, vertically integrated global healthcare group, today announced that it has purchased an [...]
Epista Launches Major Clinical Data Remediation Program with Global Pharma Leader
13/10/2025
Multi-phase initiative will remediate over 4 million clinical records across 800+ studies, ensuring inspection-ready data for global biopharma leader's digital transformation. KING OF PRUSSIA, Pa., Oct. 13, 2025 (GLOBE [...]
Neutrolis Announces Late-Breaking Oral Presentation of Clinical Results at American College of Rheumatology Convergence 2025
13/10/2025
CAMBRIDGE, Mass., Oct. 13, 2025 (GLOBE NEWSWIRE) -- Neutrolis Inc., a clinical-stage biotech company focused on targeting Neutrophil Extracellular Traps (NETs) to revolutionize the treatment of inflammatory disorders, [...]

Pages